A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: careful (81), measured (540)

Fluorouracil Folinic Acid

Description
Chemotherapy Protocol COLORECTAL CANCER FLUOROURACIL and FOLINIC ACID (Modified de Gramont) Regimen • Colorectal Cancer– Fluorou
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Fluorouracil-Folinic-Acid.pdf

ColorectalTrifluridineTipiricilVer1

Description
Chemotherapy Protocol Regimen COLORECTAL CANCER TRIFLURIDINE-TIPIRACIL  Colorectal Cancer – Trifluridine-Tipiracil Indication  Triflu
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/ColorectalTrifluridineTipiricilVer1.pdf

Cetuximab-Irinotecan (21day)

Description
Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (21 day) This regimen may require funding Regimen • Colorectal Cance
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan.pdf

Cetuximab (500)-Fluorouracil-Folinic Acid-Irinotecan

Description
Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB(500)-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)IRINOTECAN Regimen This regimen may req
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab500-Fluorouracil-FolinicAcid-Irinotecan.pdf

Everolimus Ver 1

Description
Chemotherapy Protocol PANCREATIC NEUROENDOCRINE CARCINOMA EVEROLIMUS This protocol may require funding Regimen PNET - Everolimus Indication The
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Endocrinecancer/Everolimus-Ver-1.pdf

Disclosing the minuscule risk for consent

Description
When seeking a patient's consent for treatment, we are faced daily with the prospect of trying to identify which risks we
Url
/HealthProfessionals/Clinical-law-updates/Disclosing-the-minuscule-risk-for-consent.aspx

Loncastuximab

Description
Chemotherapy Protocol LYMPHOMA LONCASTUXIMAB TESIRINE Regimen • Diffuse Large B-Cell Lymphoma (DLBCL) / High Grade B-Cell Lymphoma (HGBL) Loncastuximab Tesirine M
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Loncastuximab.pdf

AmB - Cytarabine(3000)

Description
Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA AmB- CYTARABINE (3000mg/m2) Ambulatory Regimen This regimen is for AMBULATORY CARE pathwa
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/AmB-Cytarabine-3000.pdf

Governors' Nomination Committee Terms of Reference 2025 Jan

Description
Governors’ Nomination Committee Terms of Reference Date Issued: Review Date: Document Type: 29 January 2025 January 2026 Committee Terms of Reference
Url
/Media/UHS-website-2019/Docs/Council-of-Governors/Governors-Nomination-Committee-Terms-of-Reference-2025-Jan.pdf

Cisplatin-Lomustine-Vincristine (Packer LCV3)

Description
Chemotherapy Protocol Central Nervous System CISPLATIN-LOMUSTINE-VINCRISTINE (Packer LCV3) Regimen • CNS – Cisplatin-Lomust
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CNS/Cisplatin-Lomustine-Vincristine-Packer-LCV3.pdf
381 to 390 of 1000
Previous … 37 38 39 40 41 … Next